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Clomiphene fails to revert 
hypogonadism in most male 
patients with conventionally treated 
nonfunctioning pituitary adenomas
Clomifeno não reverte o hipogonadismo na maioria dos homens com 
adenomas pituitários não funcionais tratados de forma convencional 
Rogerio Silicani Ribeiro1, Julio Abucham1
ABSTRACT
Objective: To evaluate the effect of clomiphene in men with hypogonadism and conventionally 
treated nonfunctioning pituitary adenomas (NFPA). Patients and methods: Open label, single-
-arm, prospective trial. Nine hypogonadal men (testosterone < 300 ng/dL and low/normal LH) 
with previously treated NFPA. Clomiphene (50 mg/day orally) for 12 weeks. Testosterone, estra-
diol, LH, FSH, prolactin and erectile function were evaluated before and after 10 days, 4, 8 and 
12 weeks of clomiphene treatment. Results: After clomiphene treatment, testosterone and erec-
tile function improved in only one patient. In the remaining eight patients, testosterone levels 
decreased whereas LH, FSH, and estradiol remained unchanged. Insulin sensitivity increased 
in unresponsive patients. Conclusions: Compared with hypogonadal men with prolactinomas 
under dopaminergic therapy, clomiphene treatment failed to restore normal testosterone levels 
in most patients with conventionally treated NFPA. Arq Bras Endocrinol Metab. 2011;55(4):266-71
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RESUMO
Objetivo: Avaliar o efeito do clomifeno em homens com hipogonadismo e adenoma hipofisá-
rio não funcionante (NFPA) previamente tratados. Pacientes e métodos: Aberto, braço único, 
prospectivo. Nove homens hipogonádicos (testosterona < 300 ng/dL e LH normal/baixo) com 
NFPA previamente tratados. Clomifeno (50 mg/dia oral) por 12 semanas. Testosterona, estra-
diol, LH, FSH, prolactina e função erétil foram avaliados antes e após 10 dias, 4, 8 e 12 semanas 
de clomifeno. Resultados: Após clomifeno, a testosterona e a função erétil melhoraram em um 
paciente. Em outros oito pacientes, os níveis de testosterona reduziram enquanto os níveis de 
LH, FSH, e estradiol permaneceram inalterados. A sensibilidade à insulina aumentou nos não 
respondedores. Conclusões: Em contraste com homens hipogonádicos com prolactinomas 
tratados com agonistas dopaminérgicos, a maioria dos hipogonádicos com NFPA falha em res-
taurar os níveis de testosterona durante o uso de clomifeno. Arq Bras Endocrinol Metab. 2011;55(4):266-71
Descritores
Adenoma hipofisário não funcionante; hipogonadismo hipogonadotrófico; clomifeno; testosterona
INTRODUCTION
Clinically nonfunctioning pituitary adenomas (NFPA) are usually diagnosed due to compres-
sive symptoms, most typically visual field abnormalities, 
headache and hypopituitarism.  Hypogonadotropic hy-
pogonadism in patients with NFPA is highly prevalent 
both at diagnosis and after conventional treatment with 
pituitary surgery and/or radiotherapy (1-5). Untreated 
hypogonadism decreases patient quality of life and fer-
tility and increases cardiovascular risk (6-8). 
Male hypogonadal patients are usually treated with 
testosterone replacement, most often with intramus-
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cular injections that require frequent applications and 
induce large fluctuations in serum testosterone levels, 
with corresponding fluctuations in patient energy, libi-
do, sexual performance and mood. In addition, testos-
terone replacement has an inhibitory effect on sperma-
togenesis and fertility, which is undesirable in patients 
who want to have children (7,8). 
Clomiphene is a well-known selective estrogen re-
ceptor modulator that increases gonadotropin secre-
tion via hypothalamic-pituitary action (9). Clomiphe-
ne has been extensively used in the evaluation of the 
gonadotropic axis and in the induction of ovulation. 
Clomiphene has also been shown to revert hypogo-
nadotropic hypogonadism in several conditions, such 
as falciform anemia, uremia, alcohol and steroid abu-
se, and in the stimulation of gonadotropin secretion 
in patients with sulpiride-induced hyperprolactinemia 
and gonadotropin suppression (10-14). More recently, 
we have shown that clomiphene led to the recovery of 
gonadal function in most male patients with prolacti-
nomas and persistent hypogonadism under dopamine 
agonist treatment, irrespective of prolactin levels (15). 
In this study, we evaluated the therapeutic potential of 
clomiphene in reverting hypogonadism in patients with 
conventionally treated NFPA. 
PATIENTS AND METHODS
Patients
Twelve consecutive adult male patients with NFPA, 
previously treated with surgery with or without radio-
therapy, seen during one year at the Neuroendocrine 
Unit of the Endocrinology Division, Escola Paulista de 
Medicina, Universidade Federal de São Paulo, presen-
ted hypogonadotropic hypogonadism and were consi-
dered to be included the protocol. Hypogonadotropic 
hypogonadism was defined by total testosterone levels 
below 300 ng/dL (10.5 nmol/L), and normal/low 
LH levels after at least two months of surgery. Testos-
terone replacement was discontinued for at least two 
months before evaluation. Three patients were exclu-
ded from the study due to prostate disease, limitations 
in schedule, or cognitive deficit. Nine patients comple-
ted the study. 
Study design 
This study was an interventional, open label, uncontrol-
led, single-arm, prospective trial with oral clomiphene 
citrate (Clomid®, Medley, kindly provided by Dr. Enrico 
Repetto), 50 mg/day for 12 weeks, designed to assess 
the effects of the drug on serum testosterone levels of 
male patients with NFPA previously treated with surgery. 
The secondary aims of the study were to evaluate the 
effects of clomiphene on sexual function, body compo-
sition, lipid and glucose metabolism, and quality of life.
Physical examination, erectile function and quality 
of life questionnaires, serum hormone measurements 
(testosterone, SHBG, estradiol, prolactin, LH and 
FSH), serum PSA, lipids (total, LDL and HDL cho-
lesterol, and triglycerides), glucose and insulin (before 
and after oral glucose), and body composition were all 
analyzed before and at the end of 12 weeks of clomi-
phene treatment. In addition, hormonal evaluations 
were performed at 10 days and at 4 and 8 weeks of 
treat ment, and after discontinuing clomiphene treat-
ment for 12 weeks. The study protocol was approved 
by the ethics committee of the institution, and a written 
informed consent was obtained from all participants. 
Assays
Serum testosterone, SHBG, estradiol, prolactin, LH, 
FSH, insulin and PSA were measured in fasting serum 
by automated immunochemoluminescent assays (AD-
VIA Centaur, Bayer). Free testosterone values were 
calculated from total testosterone and SHBG results 
using a fixed albumin level, as previously described 
(16). Glucose was measured in plasma using an enzy-
matic method (Hexokinase II). Total cholesterol and 
triglycerides were measured in plasma by a peroxidase 
colorimetric immunoenzymatic method. HDL choles-
terol was measured in serum using an immunoenzima-
tic method, and LDL and VLDL  were calculated.
Body composition 
Body composition [lean body mass, fat mass and bone 
mineral content (BMC)] was determined by dual-ener-
gy x-ray absorptiometry (QDR 2000-Plus, Hologic), 
according to the ICSD guidelines (17).
Questionnaires
Erectile function was evaluated using a 15-question 
survey (IIEF, international index of erectile function), 
and quality of life was evaluated using a 26-question 
survey (WHOQOL-BREF, World Health Organiza-
tion − Quality of Life). Both questionnaires were pre-
viously validated in Portuguese (18,19).
Clomiphene in pituitary adenomas
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Statistical analysis
Patients were classified as responsive and unresponsi-
ve according to their testosterone levels during treat-
ment (> 300 ng/dL or 10.5 nmol/L), in at least 2 of 3 
measurements between 4 and 12 weeks of clomiphene 
treatment. Statistical analyses were carried out using 
ANOVA or Friedman’s test according to data distri-
bution, followed by Bonferroni’s or Dunn’s post-tests, 
respectively.  Comparisons within the same group were 
performed by paired t test or Wilcoxon signed-rank test, 
according to data distribution. Comparisons between 
two independent groups were performed by unpaired t 
test or Mann-Whitney test, as appropriate. Correlations 
between two variables were calculated by Pearson coe-
fficient (r). Statistical significance was set at P < 0.05. 
Data were analyzed using GraphPad Prism 4.03 and 
GraphPad StatMate 2. Data are presented as mean ± 
standard error (SE), or as median when indicated.
RESULTS
Baseline characteristics
As shown in table 1, all nine patients that concluded 
the study had large macroadenomas at diagnosis, and 
had been previously treated at least once with pituitary 
surgery. Six patients had residual tumors after their last 
surgery. Five patients received conventional radiothe-
rapy. All patients were on stable replacement doses of 
thyroxine with normal serum FT4 levels, and five were 
on glucocorticoid replacement therapy with predniso-
ne (2.5-5.0 mg/d P.O.). Four patients had low levels 
of IGF-1, and two patients had low levels of prolactin. 
Gonadotropins, total and free testosterone and 
estradiol levels during clomiphene treatment
As shown in table 2, eight patients did not respond to 
treatment. In this group, testosterone levels not only 
failed to increase, but also decreased significantly du-
ring clomiphene treatment, whereas FSH, LH, and 
estradiol levels showed no significant changes. SHBG 
increased significantly from 18.2 ± 4 nmol/L to 31 ± 
5 nmol/L (P < 0.05), and free calculated testosterone 
decreased significantly from 3.9 ± 0.6 ng/dL to 1.9 ± 
0.6 ng/dL (0.13 ± 0.02 nmol/L to 0.06 ± 0.02, P < 
0.01) after 12 weeks of clomiphene treatment.
Only one of nine patients (patient #1) responded 
to clomiphene treatment, with increases in testosterone 
and estradiol levels. In this patient, serum SHBG and 
free testosterone levels, evaluated at baseline and after 
12 weeks of clomiphene treatment, also increased from 
32 nmol/L to 83 nmol/L and from 2.2 ng/dL (0.07 
nmol/L) to 9.4 ng/dL (0.32 nmol/L), respectively. 
After 12 weeks of clomiphene withdraw, total testos-
terone decreased to pretreatment levels [270 ng/dL 
(9.45 nmol/L)].
Table 1. Baseline characteristics of nine male patients with NFPA and persistent hypogonadism
Patient 1 2 3 4 5 6 7 8 9
Clinical presentation at diagnosis
Age 46 55 60 40 38 49 62 37 37
Initial complaint* (years) H  (1.5) H  (1) VL (1.5) H (2) VL (0.5) VL (1) LL (1.5) VL  (8) VL  (3)
Hypogonadism (years) 0.6 4 nr 2 2 0.5 1.5 nr 3
Visual impairment** 4 6 4 4 6 4 2 6 7
Tumor size*** (cm) 2 4.5 3.9 MA 2 3.8 4 3 MA
Previous treatment
TS 2 1 1 1 3 2 1 2 2
TC N N N N 2 N N 1 N
RT N N N Y Y Y N Y Y
Previous hormone replacement
Testosterone Y N Y Y Y Y Y Y Y
Thyroxine Y Y Y Y Y Y Y Y Y
Corticosteroid N Y N N N Y Y Y Y
Baseline prolactin**** 13.9 7.3 1 14.3 6.7 9.1 1.3 3.5 8
* Duration of major symptom until diagnosis; ** Number of impaired quadrants of the visual field; *** Largest diameter at diagnosis; **** Unit ng/mL; normal range: 2,1-17,7 ng/mL.
H: headache; VL: visual loss; LL: loss of libido; MA: macroadenoma (tumor size not available); TS: transsphenoidal; TC: transcranial; RT: radiotherapy; nr: not reported; y: yes, n: no.
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Table 2. Results for serum testosterone, estradiol, LH and FSH levels in male patients with NFPA and persistent hypogonadis
Patient
Total testosterone (ng/dl) Estradiol (pg/ml)
basal on clomiphene off basal on clomiphene off
0 4 wks 8 wks 12 wks 24 wks 0 4 wks 8 wks 12 wks 24 wks
1 224 631 486 810 270 57.3 38.4 51.1 83.8 29.2
2 82.3 53.1 59.5 58.5 68.5 16.5 15.5 10 10 68.5
3 152.3 117.8 94.2 74.9 89.3 10 13.8 10 19.7 89.3
4 52.5 31 13.8 25.8 42.3 10 11.6 11.2 26.1 42.3
5 206 201.8 169.4 171.6 167.8 12 17.6 10 27.2 167.8
6 246.5 71 65 48.1 114.8 16.7 26.7 15 11.7 114.8
7 157.7 86.9 83.9 81.9 435.6 10 16.5 10.9 10 435.6
8 87.1 61.3 38.4 26.3 18.5 13 18.8 10 10 18.5
9 249.3 285.1 262.5 187.1 242.7 42.8 40.1 21.5 42.9 242.7
mean ± se 154 ± 27 113 ± 31 97 ± 29 84 ± 22 147 ± 48 16 ± 4 20 ± 3 12 ± 1 19 ± 4 17 ± 2.4
P value 0.002 0.03* 0.2 0.8
Patient
LH (mU/ml) FSH (mU/ml)
basal on clomiphene off basal on clomiphene off
0 4 wks 8 wks 12 wks 24 wks 0 4 wks 8 wks 12 wks 24 wks
1 3.1 7 6.2 5.8 3 4.3 4.2 6.9 5.7 4
2 0.9 0.9 0.5 0.4 1.4 1.6 0.9 1.1 0.3 1.6
3 0.1 0.6 1.3 0.7 1.2 0.2 0.3 0.5 1.9 3.2
4 0.5 0.3 0.4 0.2 0.3 0.3 0.3 0.3 0.4 0.9
5 1 1.4 1.5 1.9 1.4 0.3 0.3 0.7 2.4 1.7
6 1.2 0.9 1 1.1 1.3 9.3 13.9 11 13.2 17.5
7 1.2 1 0.8 0.7 6.8 1.7 1.6 1.1 1.9 2
8 0.4 0.2 0.3 0.3 0.1 0.3 0.3 0.3 1.3 0.4
9 1.3 3 3.1 3.4 2.8 2.1 2.4 1.5 1.5 3.1
mean ± se 0.8 ± 0.2 1 ± 0.3 1.1 ± 0.3 1.1 ± 0.4 1.9 ± 0.7 1.9 ± 1 2.6 ± 1.6 2.4 ± 1.5 2.8 ± 1.5 3.8 ± 1.9
P value 0.7 0.54 0.3 0.1
Body composition, serum glucose, insulin, 
cholesterol and triglycerides during clomiphene 
treatment
In the eight unresponsive patients, BMI tended to in-
crease from 27.5 ± 0.6 to 27.7 ± 0.6 kg/m2 (P = 0.05). 
Fat mass increased significantly, whereas lean body 
mass, waist circumference and bone mineral density re-
mained unchanged after clomiphene treatment. Fasting 
serum glucose tended to decrease from 92 ± 2 to 85 ± 
3 mg/dl (P = 0.07), fasting insulin decreased from 18 ± 
4 to 12 ± 3 µU/mL (P < 0.05), HOMA-IR decreased 
from 4 ± 0.8 to 2.5 ± 0.6 (P < 0.05), and total choleste-
rol decreased from 214 ± 12 to 193 ± 10 mg/dL after 
clomiphene treatment in unresponsive patients, but no 
significant changes were observed in serum LDL, HDL 
and triglycerides, or in glucose and insulin levels at 120 
minutes after the oral glucose tolerance test (OGTT). 
DISCUSSION
In this study, we have shown that chronic administra-
tion of clomiphene citrate failed to recover gonadal 
function in most male patients with conventionally 
treated NFPA and persistent hypogonadotropic hy-
pogonadism. This finding is in sharp contrast to the 
high response rate (71%) we have recently observed 
in male hypogonadal patients with prolactinomas, tre-
ated with clomiphene using the same study protocol 
(15). Clomiphene failure to restore gonadal function 
in most patients with treated NFPA is likely to reflect 
a much lower functional reserve of gonadotrophic cells 
and/or GnRH neurons in these patients, as compared 
with prolactinoma patients (20). In fact, because of the 
poor efficacy of currently available medical treatment 
for NFPA, as opposed to the high efficacy of dopamine 
agonists in prolactinomas, NFPA patients are frequen-
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Table 3. Results for glucose, insulin, body composition, cholesterol and triglycerides in nine male patients with NFPA and persistent hypogonadism
Patient
Fasting glucose 
(mg/dl)
OGTT 120' glucose 
(mg/dl)
Fasting insulin  
(µU/ml) 
OGTT 120' insulin 
(µU/ml) IR HOMA ISI Matsuda
baseline after CC baseline after CC baseline after CC baseline after CC baseline after CC baseline after CC
1 121 94 108 155 99.0 25.0 110.0 163.0 29.8 5.8 0.7 1.7
2 99 85 123 151 11.7 7.8 60.0 80.3 2.9 1.6 4.1 4.1
3 93 75 80 64 27.0 10.2 42.4 10.8 6.2 1.9 2.7 8.5
4 93 100 86 82 7.6 4.4 40.8 40.1 1.7 1.1 4.5 5.9
5 94 81 129 106 36.5 30.9 285.2 65.3 8.5 6.2 1.0 3.5
6 94 90 143 102 6.7 7.5 85.3 64.6 1.6 1.7 5.0 5.5
7 96 81 193 130 13.9 15.4 176.0 106.4 3.3 3.1 1.9 2.1
8 93 86 105 109 16.2 9.9 46.2 44.6 3.7 2.1 3.3 3.6
9 78 84 74 80 21.3 12.0 59.2 65.2 4.1 2.5 2.8 5.1
mean (se)* 92 ± 2 85 ± 3 116 ± 14 103 ± 10 18 ± 3.6 12 ± 2.9 99 ± 31 60 ± 10 4 ± 0.8 2.5 ± 0.6 3.1 ± 0.5 4.8 ± 0.7
P value 0.07 0.2 0.03 0.2 0.02 0.05
Patient
Fat mass Muscle mass Total cholesterol  (mg/dl)
LDL cholesterol  
(mg/dl)
HDL cholesterol  
(mg/dl)
Triglycerides  
(mg/dl)
baseline after CC baseline after CC baseline after CC baseline after CC baseline after CC baseline after CC
1 26.5 30.1 65.9 71.8 219.0 155.0 133.0 80.0 36.0 34.0 250.0 207.0
2 14.2 16.0 56.3 57.4 224.0 233.0 144.0 144.0 40.0 43.0 198.0 228.0
3 20.1 22.1 73.1 68.9 145.0 136.0 93.0 81.0 35.0 41.0 84.0 68.0
4 26.9 29.7 56.8 55.0 214.0 179.0 130.0 113.0 45.0 41.0 196.0 123.0
5 25.0 27.7 59.8 60.6 200.0 177.0 117.0 101.0 58.0 53.0 126.0 117.0
6 21.7 21.1 63.9 63.5 255.0 219.0 ** ** 52.0 51.0 494.0 508.0
7 18.7 20.2 54.4 53.9 226.0 197.0 ** 92.0 37.0 30.0 597.0 376.0
8 25.8 27.6 61.0 59.7 204.0 204.0 131.0 120.0 33.0 51.0 199.0 208.0
9 20.9 20.6 55.5 55.4 250.0 203.0 133.0 80.0 62.0 64.0 135.0 96.0
mean (se)* 22 ± 1 23 ± 2 60 ± 2 59 ± 2 214 ± 12 193 ± 10 124 ± 7 107 ± 8 45 ± 4 46 ± 4 254 ± 66 215 ± 54
P value 0.02 0.25 0.02 0.06 0.9 0.2
CC: clomiphene; IR: insulin resistance index; ISI: insulin sensitivity index; OGTT: oral glucose tolerance test.
tly submitted to multiple surgeries and radiotherapy 
(1-5), increasing the risk of irreversible pituitary damage. 
In unresponsive patients, clomiphene not only fai-
led to increase, but also significantly decreased testos-
terone levels. This reduction may be due the inhibitory 
effect of clomiphene on LH pulsatility and/or testicu-
lar androgen biosynthesis, since there is no variation 
in LH levels (21). Clomiphene is an estrogen receptor 
agonist/antagonist, but its ultimate in vivo effects are 
dependent on the dose, target tissue and endogenous 
estrogenic activity (9). In the hypothalamus-pituitary 
axis, at low doses (25 to 50 mg/day), clomiphene is 
reportedly ineffective in prepubertal boys, but stimula-
tes gonadotropin secretion in pubertal and adult males. 
At high doses (500 mg/day), clomiphene suppresses 
gonadotropin secretion even in normal adult males 
(22,23). 
Decreased testosterone in unresponsive patients, per 
se, should impair insulin sensitivity. However, impro-
ved insulin sensitivity was observed during clomiphene 
treatment. This observation taken together with the 
decrease in testosterone and increase in SHBG levels, 
reinforce the predominance of clomiphene estrogenic 
activity in these patients. In fact, estrogen increases 
insulin sensitivity in males with aromatase deficiency 
(24,25). Improved insulin sensitivity in persistent hy-
pogonadal males during clomiphene therapy is further 
evidence that, in males, testosterone mediates insulin 
sensitivity by means of estrogen receptors.
In the only responsive patient, gonadotropin levels 
increased and testosterone levels reached the normal 
range 10 days after clomiphene therapy started, and 
remained stable thereafter. This response was similar 
to the one previously described in male patients with 
Clomiphene in pituitary adenomas
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prolactinomas under dopamine agonist treatment (15). 
Although this patient did not receive radiotherapy, he 
had been submitted to pituitary surgery twice. None-
theless, a critical hypothalamic-pituitary reserve was 
able to respond to clomiphene treatment. Considering 
the low response rate and the size of the sample we 
could not identify predictive factors related to the res-
ponse to clomiphene.
In conclusion, most patients with conventionally 
treated NFPA did not have their normal testosterone 
levels restored during clomiphene therapy. Additional 
studies with larger number of patients may identify fac-
tors that predict the response to clomiphene in patients 
with NFPA and hypogonadism. In addition, clomiphe-
ne improved insulin sensitivity even with the decrease 
in testosterone levels.
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